[Bonaphthon--a new antiviral chemotherapeutic drug].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to G N Pershin.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Bonaphthone (6-naphthoquinone-1,2) administered per os produces a prounced therapeutic effect in experimental herpetic keratitis of rabbits, induced by the virus of herpes simplex. With the topical appllication of bonaphthone in the form of an ointment the drug also produces a curative action in herpetic keratitis of rabbits. Combined application of bonaphthone locally and enterally in dealing with herpes in rabbits also acts beneficially, the same as its separate use.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Administration of an antiviral agent bonafton (1.5 mg/kg, intraperitoneally) for 5 days to mice immunized with a supraoptimal dose of ram erythrocytes (5 X 10(9)) was followed by inhibition of suppressor-cell induction in the animal spleen. An adoptive transfer of the splenic cells of these mice to syngeneic recipients caused in the latter less specific inhibition of humoral and cellular immune responses than it was during the use of splenocytes from hyperimmunized donor mice not receiving bonafton. The inhibitory effect of the drug was more manifest toward the suppressor-cells of the delayed-type hypersensitivity than the cells suppress antibody formation.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Study of the primary immune response in CBA mice which were injected with bonafton (1.5-3 mg/kg i.p.) for 3 days has revealed stimulation of antibody formation. The maximal effect as regards the humoral immune response has been recorded on the drug use in a dose of 2 mg/kg. It has been discovered that bonafton (1-3 mg/kg) also activated the cell immune response--delayed type hypersensitivity.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.